54 results about "Mouse Colon" patented technology

The invention discloses lactobacillus fermentum ZS40, which has a prevention effect on colitis, and the preservation number of the lactobacillus fermentum ZS40 is CGMCC NO.18226. The strain has high gastric acid resistance, and the survival rate of the strain treated by artificial gastric juice with the pH value of 3.0 for 3 h reaches 79.32%; and in 0.30% cholate, the growth efficiency of the strain reaches 15.31% of that of cholate-free culture. The research finds that the strain not only can inhibit mouse colon shortening, colon injury, intestinal wall thickening and other phenomena, but also can increase T-SOD and CAT activity, reduce MPO and MDA contents, regulate balance imbalance of pro-inflammatory cytokines and anti-inflammatory cytokines, and inhibit activation of NF-kappa B and MAPK signal channels so as to better relieve inflammation. In conclusion, the strain can effectively relieve mouse symptoms of colitis and can be used for preventing and treating colitis.

The invention belongs to the technical field of pharmacy, and relates to an application of magnesium isoglycyrrhizinate to preparation of a medicine for treating colitis. In a disease model of mouse acute and chronic enteritis induced by dextran sodium sulfate DSS, the magnesium isoglycyrrhizinate can effectively improve the conditions of weight loss, diarrhea, hemafecia and colonic shortening ofmice, reduce inflammatory cell infiltration and the expression level of inflammatory factors in the colons of the mice, maintain the intestinal epithelial barrier integrity, increase connexins Zo-1, occludin and E-caderin, reduce the Claudin-2 expression level, and reduce fibrosis caused by colitis. It is found for the first time that the magnesium isoglycyrrhizinate can treat colitis, clinical application of the magnesium isoglycyrrhizinate is increased, and remarkable popularization value is achieved.

The invention discloses a bifidobacterium longum and application thereof, belonging to the field of biotechnology. The bifidobacterium longum YS108R strain provided by the invention has the characteristic of producing viscous exopolysaccharide, and can obviously improve the colitis model of mice induced by DSS. The strain has a good ability to tolerate simulated gastrointestinal fluid, can significantly reduce the disease activity index of mice during DSS induction, and has an effective protective effect on colon tissue. Moreover, the Bifidobacterium longum YS108R of the present invention is isolated from the intestinal flora of healthy people, has no toxic and side effects on the human body, and has certain advantages over traditional drug treatment. The bacterial strain can be used to make probiotic bacteria powder, fermented milk, etc., and has broad market prospects.

The invention discloses a method for measuring electrophysiological activity of colon muscles of mice and application thereof. The method comprises the following steps of: performing gavage on the mice by using compound diphenoxylate suspension to establish a constipation model, selecting medical suture needles, manufacturing copper wires into copper wire electrodes, and measuring the change of electrophysiological activity of colon. Compared with the result of the control group, the result shows that the slow wave colon frequency, the frequency variation coefficient, the amplitude and the amplitude variation coefficient of the mice in a constipation group have an extremely obvious difference P which is less than 0.01. The method for measuring the electrophysiological activity of colon muscles of mice has the advantages that 1, the measuring method is easily available in raw materials, simple, practicable, high in repeatability and high in success rate; 2, the method is slight in damage to a subject and suitable for mice and other animals; 3, according to the measuring method, the change of the electrophysiological activity of colon muscles of the mice can be objectively reflected; and 4, a powerful tool is provided for researching the movement mechanism of the colon and controlling constipation in the system.

The invention belongs to the technical field of biological medicines, and particularly relates to application of choline chloride in relieving inflammatory bowel diseases. According to the invention, choline chloride is adopted to relieve mouse inflammatory bowel diseases induced by DSS. In-vivo experiments prove that a choline chloride diet can remarkably improve the decrease of the weight of the mouse after the DSS induces colitis, remarkably reduce the increase of the disease index of the mouse, improve the change of the colon length of the mouse and reduce the colon pathology score of the mouse. All the above indexes show that choline chloride can effectively relieve the inflammatory bowel diseases.

The invention relates to the application of a strain of Lactobacillus paracasei combined with CAR-T cell therapy, belongs to the field of microbial technology, and specifically discloses a strain of Lactobacillus paracasei ( Lactobacillus paracasei , MIT‑16) and its application in canine tumor immunotherapy. A strain of Lactobacillus paracasei MIT‑16 with high acid production ability was isolated and screened from the intestinal tract of mice. Modulation of the immune response plays an important role in cancer therapy. The strains are useful as immunomodulatory biotherapeutics.